CANTIL
LOE ApproachingNDAORALTABLET
Approved
Nov 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CANTIL is an oral small-molecule tablet approved in 1956 by Sanofi under NDA. The specific indication and mechanism of action are not publicly detailed in available data. This is a legacy product with a long market history.
LOE Approaching
Product is in late-stage lifecycle with low competitive pressure (30/100), suggesting a mature market with limited growth opportunities and potentially stable but declining team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is not a hiring priority at Sanofi. Working on CANTIL offers limited career growth potential given its LOE-approaching status and minimal competitive positioning.
Brand ManagerField Sales Representative
Worked on CANTIL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.